341220
Exo1
A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells by inducing tubulation and collapsing of the Golgi membrane.
同義詞:
Exo1, 2-(4-Fluorobenzoylamino)methylbenzoate, 2-(4-Fluorobenzoylamino)benzoic Acid Methyl Ester, ER Export Inhibitor I
登入查看組織和合約定價
全部照片(1)
About This Item
暫時無法取得訂價和供貨情況
推薦產品
品質等級
化驗
≥95% (HPLC)
形狀
solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
white
溶解度
DMF: 25 mg/mL
DMSO: 25 mg/mL
ethanol: 5 mg/mL
methanol: 5 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
SMILES 字串
Fc1ccc(cc1)C(=O)Nc2c(cccc2)C(=O)OC
一般說明
A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells (IC50 = 20 µM in BSC1 cells) by inducing tubulation and collapsing of the Golgi membrane and redirecting the traffic back to ER. Acts as a potent and selective modifier of Golgi ARF1 GTPase activity. Unlike another membrane traffic inhibitor Brefeldin A (BFA; Cat. No. 203729), its effect seems to be limited to Golgi, as no effect can be detected on endocytic organelles, such as endosomes and TGN (trans-Golgi network). Its inhibitory mechanism and target(s) appear to be quite different from those of BFA and thus serves as a valuable alternative that complements BFA in membrane traffic studies.
生化/生理作用
Cell permeable: yes
Primary Target
Golgi ARF1 GTPase
Golgi ARF1 GTPase
Product does not compete with ATP.
Reversible: yes
Target IC50: 20 µM inhibiting vesicular traffic from ER to Golgi in BSC1 cells
包裝
Packaged under inert gas
警告
Toxicity: Harmful (C)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他說明
Feng. Y., et al. 2003. Proc. Natl. Acad. Sci. USA100, 6469.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 3
閃點(°F)
Not applicable
閃點(°C)
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。
Chi-Ling Chiang et al.
Nature communications, 14(1), 6692-6692 (2023-10-24)
Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to target high solid tumour burden like PDAC. Here, we report
我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務